サマリー

米国の早漏症市場 2024-2028
米国の早漏症市場は、2023年から2028年にかけて4億7841万米ドルの成長が予測され、予測期間中のCAGRは10.22%で加速すると予測されます。当レポートでは、米国の早漏症市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。
現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。この市場を牽引しているのは、人々の高い使用率につながる適応外薬の高い有効性、早漏を治療するための局所薬物療法の需要、早漏を引き起こす危険因子の増加です。
Technavioの米国における早漏症市場は以下のように区分される：
投与経路別
- 経口剤
- 局所
薬剤クラス別
- SSRI
- PDE5阻害薬
- アミド麻酔薬
- その他
流通チャネル別
- 処方薬
- 一般用医薬品
本調査では、薬物送達におけるナノテクノロジーの利用が、今後数年間における米国の早漏症市場の成長を促進する主な理由の1つであるとしている。また、研究開発活動の増加や斬新なウェアラブル製品の出現は、市場の大きな需要につながる。
この調査レポートは、米国の早漏症市場を分析・予測し、以下のてこ入れを行った：
- 米国の早漏症市場の規模
- 米国の早漏症市場予測
- 米国の早漏症市場産業分析
本レポートでは、米国における早漏症市場について、Absorption Pharmaceuticals LLC、Alembic Pharmaceuticals Ltd、Amneal Pharmaceuticals Inc、Bayer AG、Cipla Ltd.、Eli Lilly and Co.、Johnson and Johnson、Lupin Ltd.、NeuroHealing Pharmaceuticals Inc.、Novartis AG、Pfizer Inc.、Prinston Pharmaceutical Inc.、Teva Pharmaceutical Industries Ltd.、Veru Inc.、VIVUS LLC、Aytu BioPharma Inc.、Royalty Pharma plc、Sebela Pharmaceuticals Inc.などです。また、米国の早漏症市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。
本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートには、主要ベンダーの分析に加え、包括的な市場およびベンダーランドスケープが含まれています。本レポートの詳細については、https://www.technavio.com/report/premature-ejaculation-disorder-therapeutics-market-in-us-industry-analysis をご覧ください。
当出版社では、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細なイメージを提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

ページTOPに戻る

目次

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary - Chart on Market Overview
o Exhibit 02: Executive Summary - Data Table on Market Overview
o Exhibit 03: Executive Summary - Chart on Country Market Characteristics
o Exhibit 04: Executive Summary - Chart on Market Segmentation by Route of Administration
o Exhibit 05: Executive Summary - Chart on Market Segmentation by Drug Class
o Exhibit 06: Executive Summary - Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary - Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 08: Parent market
o Exhibit 09: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 10: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 11: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 12: Chart on US - Market size and forecast 2023-2028 ($ million)
o Exhibit 13: Data Table on US - Market size and forecast 2023-2028 ($ million)
o Exhibit 14: Chart on US: Year-over-year growth 2023-2028 (%)
o Exhibit 15: Data Table on US: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Premature ejaculation disorder market in US 2018 - 2022
o Exhibit 16: Historic Market Size - Data Table on premature ejaculation disorder market in US 2018 - 2022 ($ million)
o 4.2 Route of Administration Segment Analysis 2018 - 2022
o Exhibit 17: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
o 4.3 Drug Class Segment Analysis 2018 - 2022
o Exhibit 18: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
o 4.4 Distribution Channel Segment Analysis 2018 - 2022
o Exhibit 19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 20: Five forces analysis - Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 23: Threat of new entrants - Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 24: Threat of substitutes - Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 25: Threat of rivalry - Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 26: Chart on Market condition - Five forces 2023 and 2028
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 27: Chart on Route of Administration - Market share 2023-2028 (%)
o Exhibit 28: Data Table on Route of Administration - Market share 2023-2028 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 29: Chart on Comparison by Route of Administration
o Exhibit 30: Data Table on Comparison by Route of Administration
o 6.3 Oral - Market size and forecast 2023-2028
o Exhibit 31: Chart on Oral - Market size and forecast 2023-2028 ($ million)
o Exhibit 32: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
o Exhibit 33: Chart on Oral - Year-over-year growth 2023-2028 (%)
o Exhibit 34: Data Table on Oral - Year-over-year growth 2023-2028 (%)
o 6.4 Topical - Market size and forecast 2023-2028
o Exhibit 35: Chart on Topical - Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Data Table on Topical - Market size and forecast 2023-2028 ($ million)
o Exhibit 37: Chart on Topical - Year-over-year growth 2023-2028 (%)
o Exhibit 38: Data Table on Topical - Year-over-year growth 2023-2028 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 39: Market opportunity by Route of Administration ($ million)
o Exhibit 40: Data Table on Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Drug Class
o 7.1 Market segments
o Exhibit 41: Chart on Drug Class - Market share 2023-2028 (%)
o Exhibit 42: Data Table on Drug Class - Market share 2023-2028 (%)
o 7.2 Comparison by Drug Class
o Exhibit 43: Chart on Comparison by Drug Class
o Exhibit 44: Data Table on Comparison by Drug Class
o 7.3 SSRIs - Market size and forecast 2023-2028
o Exhibit 45: Chart on SSRIs - Market size and forecast 2023-2028 ($ million)
o Exhibit 46: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million)
o Exhibit 47: Chart on SSRIs - Year-over-year growth 2023-2028 (%)
o Exhibit 48: Data Table on SSRIs - Year-over-year growth 2023-2028 (%)
o 7.4 PDE5 inhibitors - Market size and forecast 2023-2028
o Exhibit 49: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
o Exhibit 50: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
o Exhibit 51: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
o Exhibit 52: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
o 7.5 Amide anesthetics - Market size and forecast 2023-2028
o Exhibit 53: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
o Exhibit 55: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%)
o Exhibit 56: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%)
o 7.6 Others - Market size and forecast 2023-2028
o Exhibit 57: Chart on Others - Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Data Table on Others - Market size and forecast 2023-2028 ($ million)
o Exhibit 59: Chart on Others - Year-over-year growth 2023-2028 (%)
o Exhibit 60: Data Table on Others - Year-over-year growth 2023-2028 (%)
o 7.7 Market opportunity by Drug Class
o Exhibit 61: Market opportunity by Drug Class ($ million)
o Exhibit 62: Data Table on Market opportunity by Drug Class ($ million)
• 8 Market Segmentation by Distribution Channel
o 8.1 Market segments
o Exhibit 63: Chart on Distribution Channel - Market share 2023-2028 (%)
o Exhibit 64: Data Table on Distribution Channel - Market share 2023-2028 (%)
o 8.2 Comparison by Distribution Channel
o Exhibit 65: Chart on Comparison by Distribution Channel
o Exhibit 66: Data Table on Comparison by Distribution Channel
o 8.3 Prescription - Market size and forecast 2023-2028
o Exhibit 67: Chart on Prescription - Market size and forecast 2023-2028 ($ million)
o Exhibit 68: Data Table on Prescription - Market size and forecast 2023-2028 ($ million)
o Exhibit 69: Chart on Prescription - Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on Prescription - Year-over-year growth 2023-2028 (%)
o 8.4 OTC - Market size and forecast 2023-2028
o Exhibit 71: Chart on OTC - Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on OTC - Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on OTC - Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on OTC - Year-over-year growth 2023-2028 (%)
o 8.5 Market opportunity by Distribution Channel
o Exhibit 75: Market opportunity by Distribution Channel ($ million)
o Exhibit 76: Data Table on Market opportunity by Distribution Channel ($ million)
• 9 Customer Landscape
o 9.1 Customer landscape overview
o Exhibit 77: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 78: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 79: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 80: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 81: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 82: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 83: Matrix on vendor position and classification
o 12.3 Absorption Pharmaceuticals LLC
o Exhibit 84: Absorption Pharmaceuticals LLC - Overview
o Exhibit 85: Absorption Pharmaceuticals LLC - Product / Service
o Exhibit 86: Absorption Pharmaceuticals LLC - Key offerings
o 12.4 Alembic Pharmaceuticals Ltd.
o Exhibit 87: Alembic Pharmaceuticals Ltd. - Overview
o Exhibit 88: Alembic Pharmaceuticals Ltd. - Product / Service
o Exhibit 89: Alembic Pharmaceuticals Ltd. - Key offerings
o 12.5 Amneal Pharmaceuticals Inc.
o Exhibit 90: Amneal Pharmaceuticals Inc. - Overview
o Exhibit 91: Amneal Pharmaceuticals Inc. - Business segments
o Exhibit 92: Amneal Pharmaceuticals Inc. - Key news
o Exhibit 93: Amneal Pharmaceuticals Inc. - Key offerings
o Exhibit 94: Amneal Pharmaceuticals Inc. - Segment focus
o 12.6 Aytu BioPharma Inc.
o Exhibit 95: Aytu BioPharma Inc. - Overview
o Exhibit 96: Aytu BioPharma Inc. - Product / Service
o Exhibit 97: Aytu BioPharma Inc. - Key offerings
o 12.7 Bayer AG
o Exhibit 98: Bayer AG - Overview
o Exhibit 99: Bayer AG - Business segments
o Exhibit 100: Bayer AG - Key news
o Exhibit 101: Bayer AG - Key offerings
o Exhibit 102: Bayer AG - Segment focus
o 12.8 Cipla Ltd.
o Exhibit 103: Cipla Ltd. - Overview
o Exhibit 104: Cipla Ltd. - Business segments
o Exhibit 105: Cipla Ltd. - Key news
o Exhibit 106: Cipla Ltd. - Key offerings
o Exhibit 107: Cipla Ltd. - Segment focus
o 12.9 Eli Lilly and Co.
o Exhibit 108: Eli Lilly and Co. - Overview
o Exhibit 109: Eli Lilly and Co. - Product / Service
o Exhibit 110: Eli Lilly and Co. - Key news
o Exhibit 111: Eli Lilly and Co. - Key offerings
o 12.10 Johnson and Johnson
o Exhibit 112: Johnson and Johnson - Overview
o Exhibit 113: Johnson and Johnson - Business segments
o Exhibit 114: Johnson and Johnson - Key news
o Exhibit 115: Johnson and Johnson - Key offerings
o Exhibit 116: Johnson and Johnson - Segment focus
o 12.11 NeuroHealing Pharmaceuticals Inc.
o Exhibit 117: NeuroHealing Pharmaceuticals Inc. - Overview
o Exhibit 118: NeuroHealing Pharmaceuticals Inc. - Product / Service
o Exhibit 119: NeuroHealing Pharmaceuticals Inc. - Key offerings
o 12.12 Novartis AG
o Exhibit 120: Novartis AG - Overview
o Exhibit 121: Novartis AG - Business segments
o Exhibit 122: Novartis AG - Key offerings
o Exhibit 123: Novartis AG - Segment focus
o 12.13 Pfizer Inc.
o Exhibit 124: Pfizer Inc. - Overview
o Exhibit 125: Pfizer Inc. - Product / Service
o Exhibit 126: Pfizer Inc. - Key news
o Exhibit 127: Pfizer Inc. - Key offerings
o 12.14 Sebela Pharmaceuticals Inc.
o Exhibit 128: Sebela Pharmaceuticals Inc. - Overview
o Exhibit 129: Sebela Pharmaceuticals Inc. - Product / Service
o Exhibit 130: Sebela Pharmaceuticals Inc. - Key offerings
o 12.15 Teva Pharmaceutical Industries Ltd.
o Exhibit 131: Teva Pharmaceutical Industries Ltd. - Overview
o Exhibit 132: Teva Pharmaceutical Industries Ltd. - Business segments
o Exhibit 133: Teva Pharmaceutical Industries Ltd. - Key news
o Exhibit 134: Teva Pharmaceutical Industries Ltd. - Key offerings
o Exhibit 135: Teva Pharmaceutical Industries Ltd. - Segment focus
o 12.16 Veru Inc.
o Exhibit 136: Veru Inc. - Overview
o Exhibit 137: Veru Inc. - Business segments
o Exhibit 138: Veru Inc. - Key offerings
o Exhibit 139: Veru Inc. - Segment focus
o 12.17 VIVUS LLC
o Exhibit 140: VIVUS LLC - Overview
o Exhibit 141: VIVUS LLC - Product / Service
o Exhibit 142: VIVUS LLC - Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 143: Inclusions checklist
o Exhibit 144: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 145: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 146: Research methodology
o Exhibit 147: Validation techniques employed for market sizing
o Exhibit 148: Information sources
o 13.5 List of abbreviations
o Exhibit 149: List of abbreviations


Exhibits:
Exhibits1: Executive Summary - Chart on Market Overview
Exhibits2: Executive Summary - Data Table on Market Overview
Exhibits3: Executive Summary - Chart on Country Market Characteristics
Exhibits4: Executive Summary - Chart on Market Segmentation by Route of Administration
Exhibits5: Executive Summary - Chart on Market Segmentation by Drug Class
Exhibits6: Executive Summary - Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary - Chart on Vendor Market Positioning
Exhibits8: Parent market
Exhibits9: Market Characteristics
Exhibits10: Offerings of vendors included in the market definition
Exhibits11: Market segments
Exhibits12: Chart on US - Market size and forecast 2023-2028 ($ million)
Exhibits13: Data Table on US - Market size and forecast 2023-2028 ($ million)
Exhibits14: Chart on US: Year-over-year growth 2023-2028 (%)
Exhibits15: Data Table on US: Year-over-year growth 2023-2028 (%)
Exhibits16: Historic Market Size - Data Table on premature ejaculation disorder market in US 2018 - 2022 ($ million)
Exhibits17: Historic Market Size - Route of Administration Segment 2018 - 2022 ($ million)
Exhibits18: Historic Market Size - Drug Class Segment 2018 - 2022 ($ million)
Exhibits19: Historic Market Size - Distribution Channel Segment 2018 - 2022 ($ million)
Exhibits20: Five forces analysis - Comparison between 2023 and 2028
Exhibits21: Chart on Bargaining power of buyers - Impact of key factors 2023 and 2028
Exhibits22: Bargaining power of suppliers - Impact of key factors in 2023 and 2028
Exhibits23: Threat of new entrants - Impact of key factors in 2023 and 2028
Exhibits24: Threat of substitutes - Impact of key factors in 2023 and 2028
Exhibits25: Threat of rivalry - Impact of key factors in 2023 and 2028
Exhibits26: Chart on Market condition - Five forces 2023 and 2028
Exhibits27: Chart on Route of Administration - Market share 2023-2028 (%)
Exhibits28: Data Table on Route of Administration - Market share 2023-2028 (%)
Exhibits29: Chart on Comparison by Route of Administration
Exhibits30: Data Table on Comparison by Route of Administration
Exhibits31: Chart on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits32: Data Table on Oral - Market size and forecast 2023-2028 ($ million)
Exhibits33: Chart on Oral - Year-over-year growth 2023-2028 (%)
Exhibits34: Data Table on Oral - Year-over-year growth 2023-2028 (%)
Exhibits35: Chart on Topical - Market size and forecast 2023-2028 ($ million)
Exhibits36: Data Table on Topical - Market size and forecast 2023-2028 ($ million)
Exhibits37: Chart on Topical - Year-over-year growth 2023-2028 (%)
Exhibits38: Data Table on Topical - Year-over-year growth 2023-2028 (%)
Exhibits39: Market opportunity by Route of Administration ($ million)
Exhibits40: Data Table on Market opportunity by Route of Administration ($ million)
Exhibits41: Chart on Drug Class - Market share 2023-2028 (%)
Exhibits42: Data Table on Drug Class - Market share 2023-2028 (%)
Exhibits43: Chart on Comparison by Drug Class
Exhibits44: Data Table on Comparison by Drug Class
Exhibits45: Chart on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibits46: Data Table on SSRIs - Market size and forecast 2023-2028 ($ million)
Exhibits47: Chart on SSRIs - Year-over-year growth 2023-2028 (%)
Exhibits48: Data Table on SSRIs - Year-over-year growth 2023-2028 (%)
Exhibits49: Chart on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibits50: Data Table on PDE5 inhibitors - Market size and forecast 2023-2028 ($ million)
Exhibits51: Chart on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibits52: Data Table on PDE5 inhibitors - Year-over-year growth 2023-2028 (%)
Exhibits53: Chart on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibits54: Data Table on Amide anesthetics - Market size and forecast 2023-2028 ($ million)
Exhibits55: Chart on Amide anesthetics - Year-over-year growth 2023-2028 (%)
Exhibits56: Data Table on Amide anesthetics - Year-over-year growth 2023-2028 (%)
Exhibits57: Chart on Others - Market size and forecast 2023-2028 ($ million)
Exhibits58: Data Table on Others - Market size and forecast 2023-2028 ($ million)
Exhibits59: Chart on Others - Year-over-year growth 2023-2028 (%)
Exhibits60: Data Table on Others - Year-over-year growth 2023-2028 (%)
Exhibits61: Market opportunity by Drug Class ($ million)
Exhibits62: Data Table on Market opportunity by Drug Class ($ million)
Exhibits63: Chart on Distribution Channel - Market share 2023-2028 (%)
Exhibits64: Data Table on Distribution Channel - Market share 2023-2028 (%)
Exhibits65: Chart on Comparison by Distribution Channel
Exhibits66: Data Table on Comparison by Distribution Channel
Exhibits67: Chart on Prescription - Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on Prescription - Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on Prescription - Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on Prescription - Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on OTC - Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on OTC - Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on OTC - Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on OTC - Year-over-year growth 2023-2028 (%)
Exhibits75: Market opportunity by Distribution Channel ($ million)
Exhibits76: Data Table on Market opportunity by Distribution Channel ($ million)
Exhibits77: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits78: Impact of drivers and challenges in 2023 and 2028
Exhibits79: Overview on Criticality of inputs and Factors of differentiation
Exhibits80: Overview on factors of disruption
Exhibits81: Impact of key risks on business
Exhibits82: Vendors covered
Exhibits83: Matrix on vendor position and classification
Exhibits84: Absorption Pharmaceuticals LLC - Overview
Exhibits85: Absorption Pharmaceuticals LLC - Product / Service
Exhibits86: Absorption Pharmaceuticals LLC - Key offerings
Exhibits87: Alembic Pharmaceuticals Ltd. - Overview
Exhibits88: Alembic Pharmaceuticals Ltd. - Product / Service
Exhibits89: Alembic Pharmaceuticals Ltd. - Key offerings
Exhibits90: Amneal Pharmaceuticals Inc. - Overview
Exhibits91: Amneal Pharmaceuticals Inc. - Business segments
Exhibits92: Amneal Pharmaceuticals Inc. - Key news
Exhibits93: Amneal Pharmaceuticals Inc. - Key offerings
Exhibits94: Amneal Pharmaceuticals Inc. - Segment focus
Exhibits95: Aytu BioPharma Inc. - Overview
Exhibits96: Aytu BioPharma Inc. - Product / Service
Exhibits97: Aytu BioPharma Inc. - Key offerings
Exhibits98: Bayer AG - Overview
Exhibits99: Bayer AG - Business segments
Exhibits100: Bayer AG - Key news
Exhibits101: Bayer AG - Key offerings
Exhibits102: Bayer AG - Segment focus
Exhibits103: Cipla Ltd. - Overview
Exhibits104: Cipla Ltd. - Business segments
Exhibits105: Cipla Ltd. - Key news
Exhibits106: Cipla Ltd. - Key offerings
Exhibits107: Cipla Ltd. - Segment focus
Exhibits108: Eli Lilly and Co. - Overview
Exhibits109: Eli Lilly and Co. - Product / Service
Exhibits110: Eli Lilly and Co. - Key news
Exhibits111: Eli Lilly and Co. - Key offerings
Exhibits112: Johnson and Johnson - Overview
Exhibits113: Johnson and Johnson - Business segments
Exhibits114: Johnson and Johnson - Key news
Exhibits115: Johnson and Johnson - Key offerings
Exhibits116: Johnson and Johnson - Segment focus
Exhibits117: NeuroHealing Pharmaceuticals Inc. - Overview
Exhibits118: NeuroHealing Pharmaceuticals Inc. - Product / Service
Exhibits119: NeuroHealing Pharmaceuticals Inc. - Key offerings
Exhibits120: Novartis AG - Overview
Exhibits121: Novartis AG - Business segments
Exhibits122: Novartis AG - Key offerings
Exhibits123: Novartis AG - Segment focus
Exhibits124: Pfizer Inc. - Overview
Exhibits125: Pfizer Inc. - Product / Service
Exhibits126: Pfizer Inc. - Key news
Exhibits127: Pfizer Inc. - Key offerings
Exhibits128: Sebela Pharmaceuticals Inc. - Overview
Exhibits129: Sebela Pharmaceuticals Inc. - Product / Service
Exhibits130: Sebela Pharmaceuticals Inc. - Key offerings
Exhibits131: Teva Pharmaceutical Industries Ltd. - Overview
Exhibits132: Teva Pharmaceutical Industries Ltd. - Business segments
Exhibits133: Teva Pharmaceutical Industries Ltd. - Key news
Exhibits134: Teva Pharmaceutical Industries Ltd. - Key offerings
Exhibits135: Teva Pharmaceutical Industries Ltd. - Segment focus
Exhibits136: Veru Inc. - Overview
Exhibits137: Veru Inc. - Business segments
Exhibits138: Veru Inc. - Key offerings
Exhibits139: Veru Inc. - Segment focus
Exhibits140: VIVUS LLC - Overview
Exhibits141: VIVUS LLC - Product / Service
Exhibits142: VIVUS LLC - Key offerings
Exhibits143: Inclusions checklist
Exhibits144: Exclusions checklist
Exhibits145: Currency conversion rates for US$
Exhibits146: Research methodology
Exhibits147: Validation techniques employed for market sizing
Exhibits148: Information sources
Exhibits149: List of abbreviations